Tokyo Metrop. Org. Med. Res. These transgenic express GFP in mitochondoria. This strain is useful for morphological analysis of mitochondoria in vivo. Tg hemizygous mice have a tendency to exhibit small body size, and females of hemizygote show lower reproductive performance. Homozygous mice are infertile. C57BL/6J-Tg(CAG-Cox8/EGFP)49Rin C57BL/6J-Tg(CAG-Cox8/EGFP)49Rin Developed by Hiroshi Shitara and Hiromichi Yonekawa, Tokyo Metropolitan Institute of Medical Science in 2001. C57BL/6J background. C (3-6 months) Carrier x Noncarrier [C57BL/6JJcl] Carrier x Noncarrier [C57BL/6JJcl] CAG promoter (CMV-IE enhancer, chicken beta-actin promoter, rabbit beta-globin genomic DNA), mouse cytochrome C oxidase subunit VIII (mitochondrial inner membrane electron transport chain), HA1 epitope nucleotide sequence(synthetic), jellyfish enhancer green fluorescent protein (EGFP) cDNA 東京都臨床医学総合研究所・設楽浩志先生、米川博通先生（2001）。C57BL/6J背景。 RBRC02250 Fluorescent Proteins/lacZ System ミトコンドリアがGFPにより標識されるトランスジェニックマウス。ミトコンドリアの形態学的研究に有用。Tgヘミ型において体重の低下が認められる。繁殖能力はあるもの成績は低い。ホモ型は不妊。蛍光顕微鏡下で識別が可能。 C（3〜6か月） Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>CAGGS MTA (<A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/CAGGS_MTA.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol> The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR/DEVELOPER. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. FEBS Letters, 500, 7-11 (2001). Exp. Anim., 59, 99-103 (2010).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. For use of the BIOLOGICAL RESOURCE by a for-profit institution, the RECIPIENT must reach agreement on terms and conditions of use of it with DEPOSITOR and must obtain a prior written consent from the DEPOSITOR. The RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use with the results from the use of the BIOLOGICAL RESOURCE. Hiromichi YONEKAWA （財）東京都医学研究機構　東京都臨床医学総合研究所 米川　博通 true <a href='https://brc.riken.jp/mus/pcr02250'>Genotyping protocol -PCR-</a> 条件を付加する。利用者は事前に寄託者(開発者)の提供承諾書を得る。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。FEBS Letters, 500, 7-11 (2001). Exp. Anim., 59, 99-103 (2010).<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>営利機関の利用希望者は、事前に利用条件等につき寄託者と合意し、提供承諾を得ること。 利用者が本件リソースを利用して得られた研究成果に基づき特許等の申請、及び事業活動を行う場合は、寄託者と別途協議を行う。 Cell Biology Research mtGFP-Tg mtGFP-Tg